Physician profile
Steven M Crow
NPI 1740244078
$1,335.55
in general payments reported to CMS, 2019-2025
22 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $52.76 · 2021: $227 · 2022: $110 · 2023: $305 · 2024: $52.77 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $393.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $171.89 | 2021-2025 | Qulipta |
| Novo Nordisk INC | $128.21 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $73.40 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $69.43 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.42 | 2019-2021 | |
| Pfizer INC. | $58.24 | 2019-2023 | |
| Astellas Pharma US INC | $43.67 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $41.53 | 2019 | |
| Inspire Medical Systems, INC. | $38.76 | 2025 | Inspire |
| Aytu Biopharma, INC. | $37.79 | 2019 | |
| Allergan, INC. | $31.50 | 2020 | |
| Alvogen INC | $24.45 | 2025 | Teriparatide |
| Amgen INC. | $23.88 | 2019 | |
| Exact Sciences Corporation | $22.97 | 2025 | The Cologuard Plus Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.47 | 2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.23 | 2021 | |
| Lilly USA, LLC | $15.77 | 2023 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $15.62 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $13.49 | 2023 | Kristalose |
| Currax Pharmaceuticals LLC | $12.99 | 2021 | |
| Abbott Laboratories | $11.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Crow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.